Potential Movement of CDK 4/6 Inhibitor from Cell Cycle Arrest to Immune Activation in Breast Cancer

Pamungkas Bagus Satriyo
Additional contact information
Pamungkas Bagus Satriyo: International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei City, Taiwan

Cancer Therapy & Oncology International Journal, 2019, vol. 13, issue 1, 52-54

Abstract: Three different CDK 4/6 inhibitor was approved in a short time during 2016-2017 by FDA to treat hormone receptor-positive (HR+), HER2 negative (-) advances breast cancer patients. Since the beginning of the preclinical study, palbociclib, ribociclib, and abemaciclib were markedly suppressed proliferations of HR+/HER2- cell lines but less effective to HER2+ and Triple Negative Breast Cancer. This suppression mechanism acts through the CKD4/6-Rb-E2F axis.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555855.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555855.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:13:y:2019:i:1:p:52-54

DOI: 10.19080/CTOIJ.2019.13.555855

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().